Skip to main content
Log in or Sign up
to access My Account functionalities
Find similar products:
-
By ATC code
My Account Area
Find similar products:
-
By ATC code
Report side effect
Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to
site
Back to top
About Medicine
General Sales List
My Account Area
This information is for use by healthcare professionals
Last updated on emc: 29 Jul 2022
Quick Links
1. Name of the medicinal product
Boots Pain Relief Heat Spray
2. Qualitative and quantitative composition
| Active ingredients | |
| Ethyl nicotinate Methyl salicylate Racemic camphor | 1.1% w/w 1.25% w/w 0.625% w/w |
3. Pharmaceutical form
Topical spray.
4. Clinical particulars
4.1 Therapeutic indications
For the relief of muscular and rheumatic pains, lumbago, fibrositis, sciatica, sprains, strains and stiffness.
For topical administration.
4.2 Posology and method of administration
Adults and children over 5 years: Spray the site of pain using 2 or 3 short bursts, holding the container about 6 inches (15cm) from the skin.
Children under 5 years: Not to be used by children under 5 years.
Elderly: The normal adult dose is still appropriate in the elderly.
4.3 Contraindications
Hypersensitivity to any of the ingredients.
Children under 5 years.
4.4 Special warnings and precautions for use
For external use only.
Use sparingly as over-application can cause discomfort.
Discontinue use of the product if excessive irritation occurs.
Keep away from the eyes, face, mucous membranes and other sensitive parts of the body.
Do not use on broken or damaged skin or on open cuts.
If symptoms persist, consult your doctor.
Avoid inhalation.
Keep all medicines out of the reach of children.
4.5 Interaction with other medicinal products and other forms of interaction
No clinically significant drug interactions known.
4.6 Pregnancy and lactation
Although there are no data available to support the use of this product during pregnancy and lactation it is unlikely that use of this product would constitute a hazard to the foetus or breast fed infant.
4.7 Effects on ability to drive and use machines
No adverse effect known.
4.8 Undesirable effects
Occasional hypersensitivity reactions.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
4.9 Overdose
It is unlikely that overdosage will occur, but in the event, symptomatic treatment only should be sufficient.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Methyl salicylate has local analgesic and counter irritant properties.
Ethyl nicotinate has vasodilator properties and produces rubefacient activity.
Camphor acts as a mild analgesic, rubefacient and counter irritant.
5.2 Pharmacokinetic properties
None stated.
5.3 Preclinical safety data
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
6. Pharmaceutical particulars
6.1 List of excipients
Denatured ethanol
Hydrocarbon 40
6.2 Incompatibilities
Not applicable
6.3 Shelf life
36 months
6.4 Special precautions for storage
Pressurised container:
Protect from sunlight; do not expose to temperatures above 50° C; do not pierce or burn even when empty.
6.5 Nature and contents of container
A tinplate internally lacquered aerosol can, having an aervalve and a white/black polypropylene actuator spray fitted with a polyethylene or polypropylene cover.
Pack size: 125ml
6.6 Special precautions for disposal and other handling
Do not spray on a naked flame or any incandescent material. Do not use near, and do not place container on, polished or painted surfaces.
7. Marketing authorisation holder
The Boots Company PLC
Nottingham
NG2 3AA
8. Marketing authorisation number(s)
PL 00014/0275
9. Date of first authorisation/renewal of the authorisation
19 July 1982 / 7 December 2002
10. Date of revision of the text
04/12/2014
Delivered to you by
